Advertisement
Screener

X4 PHARMACEUTICALS, INC (XFOR) Debt / Equity

X4 PHARMACEUTICALS, INC (XFOR) Debt / Equity

  • 2023-12-31: Debt/Equity Ratio 1.07.
  • 2023-09-30: Debt/Equity Ratio 0.81.
  • 2023-06-30: Debt/Equity Ratio 0.49.
  • 2023-03-31: Debt/Equity Ratio 0.64.

Complete source-backed debt/equity ratio history.

Available history
2018-12-31 to 2023-12-31
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity Ratio
2023-12-311.07
2023-09-300.81
2023-06-300.49
2023-03-310.64
2022-12-310.45
2022-09-300.76
2022-06-301.37
2022-03-310.72
2021-12-310.53
2021-09-300.48
2020-12-310.46
2019-12-310.15
2019-09-300.25
2019-06-300.27
2019-03-310.66
2018-12-31-0.13

Annual Debt/Equity Ratio

DateDebt/Equity Ratio
2023-12-311.07
2022-12-310.45
2021-12-310.53
2020-12-310.46
2019-12-310.15
2018-12-31-0.13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Ocugen, Inc. (OCGN)United States$0.343B-6.34